The epithelial‐to‐mesenchymal transition (EMT) [26] increases tumor cell mobility and aggressiveness, whereas mutations in EGFR increase the liver metastasis risk [27], with vascular endothelial growth factor (VEGF) [28] and basic fibroblast growth factor [29]‐driven angiogenesis being crucial for metastatic tumor survival and growth in the liver [30]. Here, VEGFA is linked to metastatic neoplasm.